Background: Nutritional adherence is vital in improving clinical outcomes for chemotherapy patients. The lack of validated tools to assess dietary adherence during chemotherapy prompted the development and psychometric validation of the Chemotherapy Dietary Adherence Scale (CDAS). Objective: To develop, refine, and validate the CDAS, assessing its reliability and factorial structure through exploratory and confirmatory factor analyses. Methods: This two-phase, cross-sectional study was conducted in the Department of Medical Oncology at a tertiary care cancer centre. Data were collected from 245 chemotherapy patients over a period of two months. Phase 1 involved exploratory factor analysis (EFA) on an initial scale, followed by refinement to address weak inter-item correlations. Phase 2 validated the revised scale using confirmatory factor analysis (CFA). Reliability was assessed using Cronbach’s alpha, and statistical analysis was conducted using SPSS version 26 and Python’s semopy library. Results: The study population had a mean age of 58.13 years (SD, 9.85) and consisted predominantly of skilled workers (67.1%). The 7-item CDAS demonstrated excellent internal consistency (Cronbach’s alpha = 0.83), with subscales showing strong reliability: Nutritional Adherence (α = 0.79) and Dietary Adjustment (α = 0.81). EFA revealed a two-factor structure explaining 70.5% of the total variance. CFA confirmed this structure with exceptional model fit (χ² = 12.09, df = 13, p = 0.52; CFI = 1.00; GFI = 0.98; TLI = 1.00; RMSEA = 0.00). All items showed significant factor loadings (p < 0.001), with values ranging from 1.058 to 1.262. The moderate correlation between factors (r = 0.168, p < 0.001) indicated that they represented distinct but related dimensions of dietary adherence. Conclusions: The CDAS demonstrated robust psychometric properties, with a clear two-factor structure that captures distinct aspects of dietary adherence among chemotherapy patients. The validated scale provides a reliable and valid tool for assessing nutritional adherence and dietary adaptations during chemotherapy, potentially enhancing clinical assessment and targeted nutritional interventions.

Background: Breast cancer (BC) is now the most common cancer globally, exceeding lung cancer in 2020 with 2.3 million new cases. In 2016, India had an estimated 118,000 new cases, with a 39.1% increase in the age-standardized incidence rate between 1990 and 2016. This abstract highlights the growing global burden of BC, particularly focusing on the increasing incidence in rural India. Methods: A retrospective, observational study was conducted at the Department of Radiation Oncology, All India Institute of Medical Sciences, Kalyani, focusing on rural areas in southern West Bengal between July 2022 and January 2025 in women with biopsy-proven breast cancer. The data of the patients pertaining to histopathology, hormone status, Grade of tumour, Ki-67 Index, and demography were collected, and phenotypical classification was derived. Results: Among 456 breast cancer patients (159 premenopausal, 297 postmenopausal), 58.1% had locally advanced disease. Most presented with grade III tumours (51.8%) and high Ki-67 (67.9%). Infiltrating ductal carcinoma was predominant. Hormone receptor positivity was higher in premenopausal (64.77%) vs postmenopausal (52.52%) women; HER2 neu negative cases were more common in postmenopausal women (67.33%). Predominant phenotypic subgroups: premenopausal luminal B (40.9%), postmenopausal luminal A (34%). Interpretation and Conclusion: The findings suggest the need for tailored therapeutic strategies, especially considering the distinct phenotypic subgroups identified. Overall, these insights contribute to a better understanding of breast cancer’s epidemiology and may inform future treatment approaches and research directions in this area.

Background: In some cases of papillary thyroid carcinoma (PTC), residual tissues are observed to persistently after total thyroidectomy has been performed. In an attempt to provide further treatment, radioactive iodine (RAI) therapy is administered to obtain remission. Serum thyroglobulin (Tg) and antithyroglobulin antibodies (TgAb) are widely used biomarkers to evaluate treatment response. This study aimed to evaluate the dynamic changes in serum Tg and TgAb levels following RAI therapy in post-thyroidectomy PTC patients, and to determine the predictive value of preablation biomarkers on postablation outcomes. Methods: This observational analytic study employed a prospective cohort design. It was conducted with 51 patients with PTC who have undergone total thyroidectomy. Tg and TgAb levels were measured both pre- and one-month post-ablation. Associations were analyzed using univariate and multivariate methods. Result: The mean preablation Tg level was 82.2 ± 196.1 ng/mL, decreasing slightly to 73.7 ± 198.9 ng/mL post-ablation. However, Tg levels increased in 29.5% of patients following RAI therapy. A significant correlation was observed between preablation and postablation Tg levels (P < 0.001). Importantly, 56.9% of patients had persistently positive TgAb before and after ablation, with no observed change in status. Moreover, TgAb positivity showed no significant association with postablation Tg levels (P = 0.55), suggesting its limited utility as a post-therapy prognostic indicator. Conclusion: Preablation Tg level shows a significant correlation with postablation Tg outcomes, supporting their predictive value. However, RAI therapy showed limited effectiveness in reducing TgAb levels in certain patients, with preablation Tg being a predictor of postablation levels.

Background: Early identification of response during concurrent chemoradiotherapy (cCRT) for stage III non-small cell lung cancer (NSCLC) could critically inform clinical decision-making, particularly regarding surgical candidacy, modification or completion of therapy, and optimal integration with immunotherapies. This prospective study evaluates weekly serum procalcitonin (PCT) kinetics as a biomarker of treatment response in stage III NSCLC receiving cCRT, analyzing the potential to guide individualized care pathways. Methods: In this multicenter prospective observational study, adults aged 18–65 years with stage III NSCLC eligible for upfront concurrent chemoradiotherapy (cCRT) were enrolled. Key exclusions were elevated baseline procalcitonin (PCT > 0.1 ng/mL), active infection at baseline or during cCRT, autoimmune disease, incomplete radiotherapy, or ECOG 3–4. Serum PCT was measured at baseline and weekly during radiotherapy. Tumor response was assessed 4–6 weeks post‑cCRT by RECIST v1.1. PCT trajectories were analyzed using mixed‑design repeated‑measures ANOVA (Time × Response), with non‑parametric alternatives as needed. Logistic regression evaluated baseline and early PCT changes as predictors of response, and ROC analysis determined AUC, sensitivity, specificity, and optimal cut‑offs. Analyses were performed in SPSS v20; p < 0.05 was considered significant. Results: Of 79 screened, 73 were evaluable (5 CR, 24 PR, 27 SD, 17 PD). Responders (n=29) exhibited a consistent transient PCT peak at week 2 or 3, followed by a progressive decline. Non-responders (n=44) lacked this pattern, showing rather stable or irregular pattern of PCT levels. Repeated measures LMEM demonstrated a significant time × response effect (p<0.001). Logistic regression incorporating early PCT rise predicted response (AUC=0.84). Integration of PCT kinetics could support decisions to proceed to surgery or continue radiotherapy without interruption, obviating delays for radiologic confirmation. Conclusions: This is the first prospective report of PCT kinetics as a biomarker of cCRT response in lung cancer. A characteristic early, transient PCT rise followed by decline is associated with treatment response. Dynamic PCT monitoring can enable real‑time, individualized decision‑making, including timing for surgical evaluation and potential for mid‑treatment immunotherapeutic intensification.

Objective: Skin cancer is one of the most common malignancies globally. Considering the potential therapeutic benefits of antioxidants, this study aims to examine the trends and patterns in antioxidant application within skin cancer research over the past three decades. Methods: A bibliometric analysis was conducted on 990 English-language articles published between 1990 and 2025, retrieved from the Scopus database. Data were processed using Bibliometrix (R-based) and VOSviewer to assess publication trends, research productivity, collaboration networks, keyword co-occurrence, and thematic evolution in antioxidant-related skin cancer research. Result: The annual growth rate of publications reached 11.42%, with a sharp rise in output post-2010. The United States and China were the most productive countries, while European countries demonstrated strong international collaboration. Frequently recurring subjects included apoptosis, cancer, oxidative stress, and antioxidants. Co-occurrence analysis identified four major clusters: (1) cell biomolecular mechanisms, (2) drug metabolism, (3) malignancy agents, and (4) pharmacological innovation. Highly cited articles emphasized molecular mechanisms of antioxidants in tumor suppression. Thematic evolution showed a transition from mechanistic studies to translational and clinical research. Conclusion: Antioxidant-related research in skin cancer is rapidly evolving, with increasing global contributions and thematic diversification. This study provides a comprehensive overview of current knowledge and identifies key research gaps, including the underexploration of areas such as DNA repair, tumorigenesis, and lesser-studied antioxidant compounds, as well as the limited translation of mechanistic findings into clinical applications.

Background: Painful bone metastases are common in advanced prostate cancer. We report the clinical outcome after administration of Samarium-153 (153Sm), an emitter of beta-particles that concentrates in the areas of enhanced osteoblastic activity. Methods: This analysis included patients with confirmed mCRPC with bone metastases scheduled to receive 153Sm. All patients received 1 dose of 153Sm. Primary endpoints are short- and long-term safety, including incidence of bone marrow suppression. Secondary endpoints included 5 years survival rate. Results: Patients were enrolled from 2018 to 2019, and was followed up for 5 years. Out of 12 patients, 3 patients were lost to follow-up, and 9 patients were included. 9 patients (100%) had bone metastases only and received 153Sm injections. Most patients (88.9%) had high-volume osteoblastic lesions. The mean hot spot intensity decreased from 826,239.9 to 623,844.2 post-therapy (p = 0.036). Pain relief was significant, with the VAS score dropping from a median of 5 to 2 one day post-treatment (p = 0.003), and further improving to 1 thirty days later (p = 0.002). Drug-related treatment-emergent adverse events (TEAEs) occurred in 0% patients. At the 60-month follow-up, only 22.2% patients were found to be alive. The median time to death from samarium treatment end was recorded as 18 months. Conclusions: In this single-center cohort, 153Sm-EDTMP provided clinically meaningful pain palliation with acceptable safety. Survival estimates are descriptive of the underlying disease trajectory and should not be interpreted as a treatment effect given the non-comparative design and small sample. Prospective, multicenter studies using standardized pain and quality-of-life endpoints are warranted.

Background: Intracholecystic Papillary Neoplasm is a rare epithelial neoplasm originating in the gallbladder mucosa. It usually presents as gallbladder mass and is associated with varying degree of dysplasia or invasiveness needing high index of suspicion for proper management. Case Presentation: A 48-year-old female presented with complaints of vague upper abdominal pain for last 10 days.Ultrasound abdomen revealed polypoidal mass filling gall bladder lumen measuring 7x3.8 cm. MRCP revealed hypointense mass lesion within gallbladder lumen with its stalk at the hepatic surface of gall bladder. CT abdomen revealed heterogeneously enhancing gall bladder mass with no regional lymphadenopathy. Serum tumor markers of CEA, CA19.9 were normal. Patient underwent en bloc resection of 2 cm segment IVB liver along with gallbladder. Intraoperative frozen section specimen revealed exophytic polypoidal papillary lesion in distal body of gallbladder measuring 5x4x3 cm. Microscopic features revealed intracholecystic papillary neoplasia with low-grade dysplasia. Regional lymphadenectomy was not performed. Final diagnosis of Intracholecystic papillary neoplasm,gastric type was confirmed and patient was kept on close follow up. Conclusion: Intracholecystic papillary neoplasm of gall bladder is a rare entity presenting as intraluminal growth which require proper histopathological diagnosis. Clinical features and imaging modalities are non-specific. They have variable morphological subtypes like papillary or tubular growth patterns and may have underlying varying degree of dysplasia or invasive foci making it pertinent to perform surgical resection.They are relatively indolent with better prognosis as compared to gallbladder carcinomas. Further studies are required to precisely diagnose it and manage the various subtypes appropriately.

Background: Mucoepidermoid carcinoma (MEC) is the most common malignant salivary gland tumor, but its intraosseous (central) presentation in the jaws is extremely rare and often mimics benign odontogenic lesions. Case: We describe a 37-year-old woman with swelling and dull pain in the left mandible. Clinical and radiographic evaluation, including cone-beam computed tomography (CBCT), revealed a destructive multilocular radiolucent lesion with cortical perforation. Treatment: An incisional biopsy confirmed the diagnosis of low-grade intraosseous MEC. The lesion was surgically excised, and mandibular reconstruction was performed using an autogenous fibular bone graft. Outcome: At a three-year follow-up, the patient showed complete recovery with no evidence of recurrence. This case underscores the importance of timely diagnosis, appropriate surgical management, and long-term follow-up in intraosseous salivary gland malignancies.

Background: This prospective study evaluated the implementation of RT-PCR for the molecular monitoring of chronic myeloid leukemia (CML) patients at Sidi Bel Abbès University Hospital. Methods: We analyzed 31 consecutive CML patients (mean age 50 years, range 31–72). All patients carried the b3a2 fusion transcript. The Sokal risk distribution was as follows: high (6.45%), intermediate (51.61%), and low (41.93%). Molecular response was assessed by the *BCR-ABL1/ABL1* ratio (IS%) at diagnosis and during treatment follow-up. Results: The median BCR-ABL1/ABL1 ratio declined to 3.45% (IQR 0.66–19) at 3 months (n=12), 0.37% (IQR 0.00028–23) at 6 months (n=29), and 0.01% (IQR 0.00021–12) at 18 months (n=14). MMR rates were significantly higher in patients achieving a ratio of ≤10% at 3 months (83.3% vs. 19.0%, p<0.001) and ≤1% at 6 months (69.0% vs. 28.0%, p<0.001). Only one patient (3.2%, 95% CI 0–9.3) without an early molecular response achieved MMR by 18 months. Conclusions: Our findings confirm the clinical utility of RT-PCR for CML monitoring and emphasize the prognostic importance of early molecular response, particularly at the 3- and 6-month timepoints, in Algerian patients.

-